Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

19.25 -0.31 (-1.58%)
Streaming Delayed Price Updated: 12:57 PM EDT, May 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Fulgent Reports First Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Third Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire
Fulgent Reports First Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Third Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Exagen Inc. Appoints Paul Kim to Board of Directors
From Exagen Inc.
Via GlobeNewswire
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports First Quarter 2023 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.